Abstract
On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children's Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.
Author supplied keywords
Cite
CITATION STYLE
Tano, E., San Martin, S., Girgis, S., Martinez-Fernandez, Y., & Sanchez Vegas, C. (2021). Perimyocarditis in Adolescents after Pfizer-BioNTech COVID-19 Vaccine. Journal of the Pediatric Infectious Diseases Society, 10(10), 962–966. https://doi.org/10.1093/jpids/piab060
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
